Kehl, Kenneth L. http://orcid.org/0000-0001-5339-9797
Yang, Shihao
Awad, Mark M.
Palmer, Nathan
Kohane, Isaac S.
Schrag, Deborah
Funding for this research was provided by:
National Cancer Institute (K05CA169384)
Article History
Received: 14 October 2018
Accepted: 4 March 2019
First Online: 15 March 2019
Compliance with ethical standards
:
: Dr. Awad reports serving in a consulting or advisory role to Abbvie; ARIAD Pharmaceuticals; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Novartis; Pfizer; and Syndax. He reports holding research funding from Bristol-Myers Squibb. A portion of Dr. Palmer’s salary is supported by Aetna to provide technical support in facilitating access to data used in this analysis; Dr. Palmer also holds research funding from Union Chimique Belge (UCB). Dr. Schrag reports serving as a consultant to Pfizer and Proteus. The other authors report no conflicts of interest.
: The Harvard Medical School Institutional Review Board waived the requirement for approval, deeming analysis of the database not to be human subjects’ research. The analysis and publication of the results were approved by Aetna, which provided the data.